Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis [11]

New England Journal of Medicine

Volumn 355, Issue 19, 2006, Pages 2048-2050

  Armamento Villareal, Reina ^a   Napoli, Nicola ^a   Panwar, Vinita ^b   Novack, Deborah ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST LUKE S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; TETRACYCLINE;

ADULT; BONE BIOPSY; BONE DENSITY; BONE DEVELOPMENT; BONE TURNOVER; CASE REPORT; CLINICAL FEATURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; HUMAN; HUMAN TISSUE; IDIOPATHIC OSTEOPOROSIS; LETTER; MALE; PRIORITY JOURNAL; SPINE; TRABECULAR BONE;

EID: 33750742219     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc062268     Document Type: Letter

References (5)

1. Rosen CJ. Postmenopausal osteoporosis. N Engl J Med 2005; 353:595-603.
2. Bone HG, Hosking D, Devogelaer J, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.
3. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90: 1294-301.
4. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
5. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90:1897-9.